An allogeneic platform to generate first in class Immune Therapy ambitionning to harness patient immune system and prevent cancer resistance over treatment.
Our mission at Brenus is to provide a solution in cold solid tumors, today’s most important unmet need in oncology.
Efficacy of current approaches is compromised by drug resistances within the tumor, which is a scalable process. The population of cells constantly shifts during therapy defining cancer as a ‘moving target’.
Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.
The scalable and unique STC Platform is an allogenic technology wich mimics and represents the cellular heterogeneity of the patient’s tumor. The REPRESENTATIVITY (diversity) is ensured by cell lines selected in data base and with in vitro test. (cold tumor, hot tumor, oncogenic drivers : TP53, BRAF, KRAS,….).
STC technology allows to educate the immune system with the widest panel of neoantigens of interest.
Our technology prepares and trains the representative cells of interest: 1st physical exposition (low radiation – heatchock) and a second chemical one (clinical cytotoxic molecules). The ANTIGENICITY (plasticity) of our solution is ensured by more than 200 neo antigens expressed on the cell surface. The neo antigens are TAA (tumor Asossiated Antigens) – TSA (Tumor Specific Antigens) which constitute the largest panel of resistance factors.
In a very innovative way, and to ensure the IMMUNOGENICITY of our solution, a recognition tag associated with surface neoAntigens is added by Haptenization. This step makes the solution, already representative and antigenic, visible by the patient’s immune system, therefore very Immunogenic.
Facts about colorectal cancer
STC-1010 is targeting MSS and MSI-H population
STC-1010 has a robust and validated preclinical data pack showing
An OFF-THE-SHELF technology allowing control on time and cost of the manufacturing process
Successful exits to top Healthcare companies
GMP manufacturing of cell therapies and vaccines
Previous roles at Roche, Merck
IPO & Licencing deals (< 100 M e) / Life science & Private Equity
Previous roles at LEK Consulting, Biocorp
Pharm D ; ESSEC
Specialized in medical oncology & immunooncology
Previous roles at Roche, Takeda Oncology
Pharm D ; HEC Paris
Specialized in innovative therapies : Gene, Stem cell, RNA, …
Previous roles at Merck, Biogen, Chieisi
MD, PhD, Director of early clinical unit,
head of “Cancer and adaptative immune response” team,
CGFL, Dijon (FR).
PhD. Head of Preclinical study department
“drug resistance and new cancer therapies”,
IRCM, Montpellier (FR)
Head of Early Phase Trials and Sarcoma units; Institut Bergonié, Bordeaux (FR)
Head of Precision medicine new program; Intsitut Gustave Roussy, Paris(FR)
MD, PhD. Coordinator of early phase oncology trial CITOHL
HCL, Lyon (FR)
MD, PhD. Dept Discovery of novel cancer I/O & vaccins,
Johns Hopkins, Baltimore (US)
MD, PhD., Head of European network of academic lead investigators for innovative clinical research ONCODISTINCT.
Head of The Oncology Medicine Dept at Jules Bordet Cancer Institute, Brussels (BE)